Natural history and comorbidities of generalised and partial lipodystrophy syndromes in Spain

Front Endocrinol (Lausanne). 2023 Nov 16:14:1250203. doi: 10.3389/fendo.2023.1250203. eCollection 2023.

Abstract

The rarity of lipodystrophies implies that they are not well-known, leading to delays in diagnosis/misdiagnosis. The aim of this study was to assess the natural course and comorbidities of generalised and partial lipodystrophy in Spain to contribute to their understanding. Thus, a total of 140 patients were evaluated (77.1% with partial lipodystrophy and 22.9% with generalised lipodystrophy). Clinical data were collected in a longitudinal setting with a median follow-up of 4.7 (0.5-17.6) years. Anthropometry and body composition studies were carried out and analytical parameters were also recorded. The estimated prevalence of all lipodystrophies in Spain, excluding Köbberling syndrome, was 2.78 cases/million. The onset of phenotype occurred during childhood in generalised lipodystrophy and during adolescence-adulthood in partial lipodystrophy, with the delay in diagnosis being considerable for both cohorts. There are specific clinical findings that should be highlighted as useful features to take into account when making the differential diagnosis of these disorders. Patients with generalised lipodystrophy were found to develop their first metabolic abnormalities sooner and a different lipid profile has also been observed. Mean time to death was 83.8 ± 2.5 years, being shorter among patients with generalised lipodystrophy. These results provide an initial point of comparison for ongoing prospective studies such as the ECLip Registry study.

Keywords: atherosclerotic cardiovascular disease; body composition; diabetes mellitus; generalised lipodystrophy; hypertriglyceridaemia; mortality; partial lipodystrophy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Humans
  • Lipodystrophy* / diagnosis
  • Lipodystrophy* / epidemiology
  • Lipodystrophy* / genetics
  • Lipodystrophy, Congenital Generalized* / diagnosis
  • Lipodystrophy, Congenital Generalized* / epidemiology
  • Prospective Studies
  • Spain / epidemiology
  • Syndrome

Supplementary concepts

  • Lipodystrophy, Partial, Acquired

Grants and funding

This study was supported by the Instituto de Salud Carlos III (grant PI22/00514) and co-funded by the European Union, and an intramural grant from the Xunta de Galicia, ED431B 2020/37. AF-P receives funding from the Fundación Alfonso Martín Escudero. SS-I was awarded a Research Fellowship, granted by the Asociación Española de Familiares y Afectados de Lipodistrofias (AELIP).